Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Winston

Showing results (201-210 of 241) with videos related to

Pageof 25
Sort By:
AIDS (London, England)|October 17, 2018
Do people living with HIV experience greater age advancement than their HIV-negative counterparts?Davide De Francesco, Ferdinand W Wit, Alexander Bürkle, et al.
Antiviral Therapy|September 6, 2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
European Journal of Neurology|December 17, 2010
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era, Lucy Garvey, Alan Winston, et al.
Clinical and Translational Medicine|June 12, 2026
Refining inflammatory profiles linked to cardiometabolic outcomes in people with HIV using recursive feature addition modellingRachel MacCann, Dana Alalwan, Gurvin Saini, et al.
Journal of Neurovirology|May 20, 2016
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemiaSam Nightingale, Anna Maria Geretti, Apostolos Beloukas, et al.
Journal of Virus Eradication|July 11, 2024
Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trialJasmini Alagaratnam, Wolfgang Stöhr, Elizabeth Hamlyn, et al.
The Journal of Antimicrobial Chemotherapy|February 26, 2013
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoringAlan Winston, Sophie Jose, Sara Gibbons, et al.
HIV Medicine|October 18, 2023
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023Juan Ambrosioni, Laura Levi, Jasmini Alagaratnam, et al.
Pageof 25

Showing results (201-210 of 241) with videos related to

Sort By:
Pageof 25
AIDS (London, England)|October 17, 2018
Do people living with HIV experience greater age advancement than their HIV-negative counterparts?Davide De Francesco, Ferdinand W Wit, Alexander Bürkle, et al.
Antiviral Therapy|September 6, 2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
European Journal of Neurology|December 17, 2010
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era, Lucy Garvey, Alan Winston, et al.
Clinical and Translational Medicine|June 12, 2026
Refining inflammatory profiles linked to cardiometabolic outcomes in people with HIV using recursive feature addition modellingRachel MacCann, Dana Alalwan, Gurvin Saini, et al.
Journal of Neurovirology|May 20, 2016
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemiaSam Nightingale, Anna Maria Geretti, Apostolos Beloukas, et al.
Journal of Virus Eradication|July 11, 2024
Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trialJasmini Alagaratnam, Wolfgang Stöhr, Elizabeth Hamlyn, et al.
The Journal of Antimicrobial Chemotherapy|February 26, 2013
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoringAlan Winston, Sophie Jose, Sara Gibbons, et al.
HIV Medicine|October 18, 2023
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023Juan Ambrosioni, Laura Levi, Jasmini Alagaratnam, et al.
Pageof 25